EMB-ML Expression, Molecular Biology and MacroLab Core

EMB-ML 表达、分子生物学和 MacroLab 核心

基本信息

项目摘要

The overall goal of SBDR3 is to achieve mechanistic, predictive biology for cancer interventions through structural and functional understanding of DNA repair machines. The major challenges faced by SBDRS include: (1) efficient reconstitution and assembly of full-length and modified proteins and complexes that control integrity of the genome, (2) determining structures of flexible multi-protein complexes in solution, and (3) linking structures to biochemistry and cellular phenotypes. We propose to integrate the highly successful Expression and Molecular Biology Core that was developed at Lawrence Berkeley National Lab during the two previous SBDR funding periods with the MacroLab, a collaborative, high throughput (HT) biomolecular engineering facility on the UC Berkeley campus, to form a new EMB-ML Core for meeting the increased needs of SBDRS. The combined EMB-ML Core will address SBDRS challenges by providing dedicated Core staff and centralized resources, approaches, and reagents to overcome the bottlenecks common to different projects that are often insurmountable for a single research lab. The newly structured EMB-ML Core will serve as both a production and development resource for all six Projects, and will provide a pipeline for customized and HT construction of expression vectors, large-scale cell production, and protein interaction validation. The EMB component will provide rational design and customized expression vector construction, validation of protein-protein and protein-DNA interactions, large-scale production and expression of recombinant protein constructs in E. coli and insect cells, purification of recombinant proteins when needed for particular projects, and archiving of critical research reagents. The complementary ability to carry out rapid HT cloning, mutagenesis, and bacterial expression testing will be provided by the MacroLab. Importantly, developmental efforts in the MacroLab will be aimed at providing new technologies and platforms for further increases in throughput and yields, which will also be fed back into the EMB component. Innovative technologies include 1) creating automated (96-well) cloning and expression platforms in eukaryotic cells; 2) implementing semi-automatic polycistronic and polypromoter vector construction; and 3) developing a HT cell-free protein production system. The integrated EMB-ML Core thus offers a robust blend of established and new technologies, and efficiently provides reagents to jump-start Project efforts aimed at characterizing transient interactions and dynamic conformations that control the assembly and function of multi-protein complexes responding to DNA damage.
SBDR 3的总体目标是通过对DNA修复机器的结构和功能的理解,实现癌症干预的机制性、预测性生物学。SBDRS面临的主要挑战包括:(1)控制基因组完整性的全长和修饰蛋白质和复合物的有效重建和组装,(2)确定溶液中柔性多蛋白质复合物的结构,以及(3)将结构与生物化学和细胞表型联系起来。我们建议将劳伦斯伯克利国家实验室在前两个SBDR资助期间开发的非常成功的表达和分子生物学核心与MacroLab(加州大学伯克利分校校园内的协作高通量(HT)生物分子工程设施)整合在一起,以形成新的EMB-ML核心,以满足SBDRS不断增长的需求。合并后的EMB-ML核心将通过提供专门的核心工作人员和集中的资源,方法和试剂来解决SBDRS挑战,以克服不同项目常见的瓶颈,这些瓶颈通常是单个研究实验室无法克服的。新结构的EMB-ML Core将作为所有六个项目的生产和开发资源,并将为表达载体的定制和HT构建,大规模细胞生产和蛋白质相互作用验证提供管道。EMB组件将提供合理的设计和定制的表达载体构建,蛋白质-蛋白质和蛋白质-DNA相互作用的验证,重组蛋白构建体在E.大肠杆菌和昆虫细胞,特定项目所需的重组蛋白纯化,以及关键研究试剂的存档。MacroLab将提供进行快速HT克隆、诱变和细菌表达检测的补充能力。重要的是,MacroLab的开发工作将旨在提供新的技术和平台,以进一步提高吞吐量和产量,这也将反馈到EMB组件。创新技术包括1)在真核细胞中创建自动化(96孔)克隆和表达平台; 2)实施半自动多顺反子和多启动子载体构建; 3)开发HT无细胞蛋白质生产系统。因此,集成的EMB-ML Core提供了成熟技术和新技术的强大组合,并有效地提供了启动项目工作的试剂,旨在表征控制响应DNA损伤的多蛋白质复合物的组装和功能的瞬时相互作用和动态构象。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Priscilla K. Cooper其他文献

Priscilla K. Cooper的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Priscilla K. Cooper', 18)}}的其他基金

Genomic Instability from Loss of XPG, a BRCA1/2 Partner: Role in Ovarian Cancer?
XPG(BRCA1/2 伙伴)缺失导致基因组不稳定:在卵巢癌中的作用?
  • 批准号:
    8885778
  • 财政年份:
    2014
  • 资助金额:
    $ 56.16万
  • 项目类别:
Novel Interactions of DNA Repair Processes in Replication Fork Maintenance
复制叉维护中 DNA 修复过程的新相互作用
  • 批准号:
    8404020
  • 财政年份:
    2012
  • 资助金额:
    $ 56.16万
  • 项目类别:
Novel Interactions of DNA Repair Processes in Replication Fork Maintenance
复制叉维护中 DNA 修复过程的新相互作用
  • 批准号:
    8246242
  • 财政年份:
    2012
  • 资助金额:
    $ 56.16万
  • 项目类别:
Novel Interactions of DNA Repair Processes in Replication Fork Maintenance
复制叉维护中 DNA 修复过程的新相互作用
  • 批准号:
    8758773
  • 财政年份:
    2012
  • 资助金额:
    $ 56.16万
  • 项目类别:
Novel Interactions of DNA Repair Processes in Replication Fork Maintenance
复制叉维护中 DNA 修复过程的新相互作用
  • 批准号:
    8572128
  • 财政年份:
    2012
  • 资助金额:
    $ 56.16万
  • 项目类别:
Environmental Mutagen Society 48th Annual Meeting
环境诱变剂学会第48届年会
  • 批准号:
    7614132
  • 财政年份:
    2008
  • 资助金额:
    $ 56.16万
  • 项目类别:
Transcription-Coupled & Replication-Associated Excision Repair
转录偶联
  • 批准号:
    7152382
  • 财政年份:
    2006
  • 资助金额:
    $ 56.16万
  • 项目类别:
Gordon Research Conference on Mammalian DNA Repair
戈登哺乳动物 DNA 修复研究会议
  • 批准号:
    7018524
  • 财政年份:
    2003
  • 资助金额:
    $ 56.16万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8555262
  • 财政年份:
    2001
  • 资助金额:
    $ 56.16万
  • 项目类别:
Replication-Associated Repair and Replication Fork Maintenance
复制相关修复和复制叉维护
  • 批准号:
    8555254
  • 财政年份:
    2001
  • 资助金额:
    $ 56.16万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 56.16万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 56.16万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 56.16万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.16万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 56.16万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 56.16万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 56.16万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 56.16万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 56.16万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 56.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了